Deep Tech Startups

GigaCrop develops agricultural biotechnology to improve photosynthesis in crop plants through enzyme engineering, enabling more sustainable and efficient food and materials production. The company focuses initially on major crops like corn and soybean, with plans to expand to plants for biomanufacturing.

1 investor

Permeasis Therapeutics is developing a Membrane Translocation Domain (MTD) platform that enables intracellular delivery of proteins and other large therapeutic macromolecules to the cytosol and intracellular compartments. The company initially targets genetically defined diseases where delivering functional proteins inside cells could have therapeutic impact.

1 investor

Perseo Pharma is a biotech spin-off from the University of Applied Sciences in Basel, Switzerland, developing enzyme immobilization and bioconjugation technologies for therapeutic applications. The company focuses on creating novel platforms for drug delivery and enzyme-based therapies targeting inborn errors of metabolism and other rare diseases.

1 investor

Perseus SENOLYTIX is a gerotherapeutics company developing senolytic peptides to target senescent cells and restore cellular balance in aging organisms. The company focuses on translating scientific discoveries into therapeutics addressing fundamental mechanisms of aging.

1 investor

Parsian Tarava manufactures needle-style reusable electrodes for electroporation applications in gene transfer and drug delivery across in vivo, ex vivo, and in ovo conditions. The electrodes are designed for use in research, biomedical, genetic, and pharmaceutical settings.

1 investor

PETAL Solutions provides turbine technology consulting and aerothermal expertise, leveraging advanced computational fluid dynamics and engine modeling capabilities. The company serves aerospace, power generation, and turbomachinery clients requiring research, design optimization, and technical consulting.

1 investor

Petrabytes provides drone data platform services, offering geospatial intelligence and data analysis capabilities across energy, healthcare, and transportation sectors.

1 investor

PexMachina develops physics-based molecular simulation for drug discovery, using quantum-ready computational chemistry and AI agents to predict properties like binding, stability, and oral availability of peptides. It delivers its PexAgent as an MCP service that integrates into LLM platforms such as Claude and Gemini, letting pharmaceutical researchers run molecular simulations via natural language within existing R&D workflows.

1 investor

Peytant develops amnion-derived membrane coverings using human placental tissue to reduce the body's foreign body response in implants used for luminal disease treatment. The company's products are designed to increase patency and help clinicians manage vascular and other luminal conditions.

1 investor

Pfenex provides a Pseudomonas fluorescens-based microbial expression platform for manufacturing recombinant proteins, antibodies, and biologics at scale. The platform supports development from construct to production strain and enables technology transfer to CDMOs and manufacturing partners.

1 investor

Phanes Therapeutics develops oncology and metabolic disease therapeutics targeting cell cycle regulators and related pathways. The company operates from San Diego with operations including a research site in Shanghai.

1 investor

Phantom Photonics develops quantum-enhanced sensing technologies designed to operate in challenging environments where conventional sensors fail. The company serves industries requiring advanced measurement and observation capabilities in conditions others cannot access.

1 investor

PhmaPlanter develops biotechnology platforms for recombinant proteins, antibody development, gene editing, nutraceutical research, and advanced cellular technologies including gas vesicles and organoid culture systems.

1 investor

Phase Shift develops custom alloys using an AI and multi-scale simulation platform that designs, optimizes, and evaluates new material chemistries. It serves engineering industries such as aerospace, automotive, energy infrastructure, and medical devices with bespoke materials tailored to specific property requirements.

1 investor

Phaseshift develops meta-optical systems, using metasurface research to build integrated photonics and advanced optical components for next-generation optical systems. The company draws on expertise in quantum optics, nanophotonics, and optical engineering, with operations in India.

1 investor

Phasic Energy designs and manufactures advanced heat exchangers that offer higher heat transfer, lower pressure drop, and compact form factors compared to conventional designs. Its products serve critical infrastructure sectors including data center thermal management, defense and aerospace, geothermal energy, and industrial waste heat recovery.

1 investor

Phasor Solutions develops and procures technology spanning chip design, software, and artificial intelligence, with a focus on high-availability, secure systems for demanding operational environments including on-the-move deployments. Its offerings appear aimed at defense or mission-critical operational use.

1 investor

Phenota develops automation technology for hematology laboratories, applying Raman spectroscopy to routine blood testing for real-time analysis. It targets clinical diagnostic labs with tools built around their workflow.

1 investor

PhenoTap develops KetoTap Core, a patent-pending BHB oxidase enzyme designed for reliable, affordable, real-time ketone measurement in blood test strips and continuous monitors. It offers the enzyme as a drop-in technology for device makers building glucose-style sensors, targeting continuous ketone monitoring for health and therapeutic applications.

1 investor

Phi Optics develops quantitative phase imaging (QPI) technology that upgrades existing microscopes to enable non-invasive, real-time 3D imaging of live cells, tissues, organoids, and small organisms without labels or specimen damage. The technology serves research institutions and clinical laboratories in life sciences and diagnostics.

1 investor

Phiex Technologies develops interactive materials designed to mitigate issues caused by pathogens across multiple industries, including applications such as making sterile devices and protecting individuals exposed to the elements. The company offers this material technology without requiring machines or chambers.

1 investor

Philolabs builds a verification layer for visual AI, focused on alignment and safety infrastructure for video understanding and generation models. It serves frontier AI labs training multimodal visual intelligence systems, operating in the AI alignment and machine learning space.

1 investor

Phinity builds AI agents that design, verify, and tape out custom chips end-to-end, aiming to let users describe a chip and receive a GDS file in weeks. It operates in the semiconductor design automation space using AI-driven agents.

1 investor

Phinomics is a cancer drug discovery platform that captures extrachromosomal circular DNA (the "Circulome") at high resolution from matched tumor and normal patient samples, integrating it with DNA, RNA, epigenetics, and proteomics into a multi-omic knowledge graph. It applies explainable AI to this data to identify novel therapeutic targets, resistance mechanisms, and patient stratification biomarkers for oncology therapeutics development.

1 investor